Taking into account that chemokine-binding peptides attenuate atherosclerosis progression through CCL5 neutralization and CCL5/CXCL4 heterodimer disruption (35), the structural data obtained here could be used as a starting point for development of Evasin-4–based chemokine-binding peptides and peptidomimetics for the treatment of atherosclerosis and inflammation-associated cardiovascular diseases. Here, PF4 is linked to cardiovascular disorder.